Further studies have investigated the combination of anti-CD19/CD22 CAR-T-cell therapy with allo-HSCT (335) and showed an overall survival rate of 55.6% in a cohort of heavily pretreated r/r BL patients. The gene discussed is CD22; the disease is Burkitt lymphoma.